Drug Profile
PCUR 101
Alternative Names: PCUR-101Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Pellficure Pharmaceuticals
- Class Antineoplastics; Naphthoquinones; Small molecules
- Mechanism of Action Protein kinase C epsilon inhibitors; Proto oncogene protein c-akt inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 04 Mar 2021 Phase-I clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Australia (PO) (NCT04677855)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) in USA (PO, Capsule)
- 21 Dec 2020 Pellficure Pharmaceuticals plans a phase I trial for Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy) in Australia (PO) (NCT04677855) (PCUR101-003)